本帖最后由 老马 于 2012-1-13 21:20 编辑 " ^& G. w/ n; M3 C8 b
9 O- V, v' O& r; H9 Y爱必妥和阿瓦斯丁的比较
1 \0 `/ P& ?4 ?/ L: i# E' Y
6 Q4 |4 ~5 x: j( p, whttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
6 [) h' h" | w# o% {8 V
* ]5 T% f4 ?" k. _1 S
* B% Z$ _! h/ y: i7 X
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/' P7 d& {+ k' B
==================================================
) B2 B) ~# L7 F' b% fOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)4 c$ M0 W' l) j! v8 F$ T! K
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.1 k, Y5 x' F- o4 V' F! U" S
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
8 f" ]0 i4 w% n8 A& X4 A
|